Last reviewed · How we verify
Toviaz (FESOTERODINE)
Toviaz (fesoterodine) is a small molecule drug developed by Pfizer that targets the muscarinic acetylcholine receptor M2. It is used to treat bladder muscle dysfunction, including overactive bladder, increased urinary frequency, urge incontinence of urine, and urgent desire to urinate. Toviaz was FDA approved in 2008 and is currently owned by Pfizer. The commercial status of Toviaz is patented, but it has multiple generic manufacturers. Key safety considerations include the potential for dry mouth, constipation, and blurred vision.
At a glance
| Generic name | FESOTERODINE |
|---|---|
| Sponsor | Pfizer |
| Drug class | fesoterodine |
| Target | Muscarinic acetylcholine receptor M2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2008 |
Approved indications
- Bladder muscle dysfunction - overactive
- Increased Urinary Frequency
- Urge incontinence of urine
- Urgent desire to urinate
Common side effects
- Dry mouth
- Constipation
- Dry throat
- Nausea
- Dyspepsia
- Dry eyes
- Urinary retention
- Cough
- ALT increased
- GGT increased
- Edema peripheral
- Back pain
Drug interactions
- atazanavir
- boceprevir
- carbamazepine
- conivaptan
- fosphenytoin
- indinavir
- itraconazole
- ketoconazole
- mibefradil
- nefazodone
- nelfinavir
- phenobarbital
Key clinical trials
- Deprescribing dRrugs for Overactive Bladder in General Practice (DROP) (NA)
- Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis (EARLY_PHASE1)
- Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
- Fall Prevention in Older Adults With OAB (PHASE4)
- Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics (PHASE4)
- Drug Use Investigation for Toviaz
- BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Toviaz CI brief — competitive landscape report
- Toviaz updates RSS · CI watch RSS
- Pfizer portfolio CI